genentech inc. said 0 third-quarter profit more than doubled to $ 11.4 million , or 13 cents a share , from a depressed 1988 third-quarter performance of $ 5.3 million , or six cents a share . revenue rose 23 % to $ 100 million from $ 81.6 million . net product sales accounted for $ 76 million , up from $ 57.5 million a year earlier . sales of the heart drug tpa were $ 43.6 million , better than last year 's depressed third period when the company sold just $ 29.1 million of the drug . but tpa sales fell below levels for this year 's first and second quarter sales of $ 48 million , cooling investors . genentech stock fell 12.5 cents in trading yesterday on the new york stock exchange to $ 20.125 . in the nine months , net income slid 21 % to $ 28.4 million , or 33 cents a share , from $ 36 million , or 42 cents a share . revenues climbed 18 % to $ 289 million from $ 245.3 million . `` we continue to be on target for ... increasing tpa sales 20 % to 25 % this year , '' said founder and chief executive officer robert swanson . but some analysts remain sour on the company . `` tpa sales are down quarter to quarter . expenses are flat and that 's a good sign . there 's contract revenue from -lcb- limited research and development -rcb- partnerships . but i still think 0 the fundamentals are poor , '' said denise gilbert , an analyst with montgomery securities in san francisco . genentech faces competition in the cardiac-drug market from smithkline beecham plc 's heart drug eminase , expected to receive market approval shortly . and genentech is n't likely to have any new products ready for market until at least 1992 , ms. gilbert added 0 . `` the company 's stock is trading at 40 times next year 's numbers , and that 's too much , '' she said . on the plus side , genentech is benefiting from a lower tax rate due to its research outlays , giving a boost to earnings , she said 0 .